New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.
Blackstone Life Sciences ("BXLS") today announced a research and development funding agreement to advance the clinical ...
High-dose daunorubicin improved complete response rates in patients aged 60 and younger and survival in those younger than 50. Despite considerable advances during the past 20 years in the diagnostic ...
Although allogeneic hematopoietic cell transplantation (allo-HCT) remains the backbone of curative treatment for the majority of fit adults diagnosed with AML, there is indeed a subset of patients for ...
InvestorsHub on MSN
Aptevo shares drop despite encouraging AML trial results
Aptevo Therapeutics Inc. (NASDAQ:APVO) shares plunged about 18% on Tuesday even after the company reported promising interim clinical results for its acute myeloid leukemia (AML) treatment candidate, ...
Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute ...
Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study We performed a population-based ...
Leukemia in older adults causes symptoms like weight loss, fatigue, and night sweats. Your outlook depends on the type of leukemia you have. Leukemia is a type of cancer that affects the blood cells, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results